| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.9 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.0065 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |